Project 2: Extracellular Glycosylation and Blood Cell Production

项目2:细胞外糖基化和血细胞生产

基本信息

  • 批准号:
    10545016
  • 负责人:
  • 金额:
    $ 60.99万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-01-01 至 2025-12-31
  • 项目状态:
    未结题

项目摘要

Project 2 – Project Summary Maintaining hematopoiesis is critical for life. Generating the proper numbers of functional blood cells across all lineages requires cell-intrinsic developmental programs, but these programs require guidance from cell-extrinsic mechanisms that correctly convey the physiologic needs for these cells. Glycans on the cell surface and in the extracellular milieu reside at the interphase through which the cell-extrinsic cues are conveyed. The overarching Program Hypothesis is that cell-intrinsic and extrinsic glycan-mediated mechanisms regulate maintenance, differentiation, and function of hematopoietic cells. Glycosyltransferases such as the sialyltransferase ST6GAL1 are also residents of the extracellular milieu. Our preliminary data point to a role for the extracellular, or extrinsic ST6GAL1, and possibly other glycosyltransferases in the marrow to influence hematopoietic decisions on multiple levels of blood cell development. Outside of the marrow, platelets upon activation release the sialic acid donor substrate required to drive extrinsic sialyltransferase catalysis. Together with Project 1, we will explore the idea that megakaryocytes, the precursors of platelets, control marrow extrinsic sialylation by a similar mechanism. Together with Project 3, we have uncovered a totally unexpected interaction between glycosaminoglycan components of the extracellular matrix with ST6GAL1, and we have identified a number of GAG-mimetics with striking ability to modulate extrinsic ST6GAL1 sialylation on target cells. Disturbed hematopoiesis with highly heterogenous presentation and varied underlying driver mutations is the defining hallmark of clonal myeloid diseases such as myeloproliferative neoplasms (MPN) and myelodysplastic syndromes (MDS). However, a key common feature of MPN and MDS is dysplastic megakaryocytes with altered circulating platelet numbers and function. Our preliminary data point to distinct glycosylation signatures associated with platelets from patients of these diseases, suggesting fundamental alterations to the bone marrow environment and the megakaryocytes that produce the platelets. We hypothesize that glycosylation, especially extrinsic glycosylation, regulates blood cell homeostasis, ultimately impacting the number and function of circulating blood cells in health and in disease. We will test this hypothesis in three Specific Aims to 1) understand how extrinsic ST6GAL1 regulates HSPC maintenance; 2) understand how extrinsic sialylation in the marrow is regulated; and 3) initiate a first-time study on how glycosylation is modified in clinical MDS and MPN and in mouse models. The proposed study is expected to yield transformative understanding of extrinsic glycosylation in cell-niche interactions critical to maintaining blood cell production. This is also a pioneering investigation into the glycoscience of clinical MDS and MPN, with potential for novel therapeutics and diagnostics.
项目2 -项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Joseph TY Lau其他文献

Joseph TY Lau的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Joseph TY Lau', 18)}}的其他基金

Project 2: Extracellular Glycosylation and Blood Cell Production
项目2:细胞外糖基化和血细胞生产
  • 批准号:
    10321581
  • 财政年份:
    2021
  • 资助金额:
    $ 60.99万
  • 项目类别:
Project 2: Extracellular Glycosylation and Blood Cell Production
项目2:细胞外糖基化和血细胞生产
  • 批准号:
    10088969
  • 财政年份:
    2021
  • 资助金额:
    $ 60.99万
  • 项目类别:
ST6Gal-1 Sialyltransferase in Inflammation
ST6Gal-1 唾液酸转移酶在炎症中的作用
  • 批准号:
    10265723
  • 财政年份:
    2020
  • 资助金额:
    $ 60.99万
  • 项目类别:
ST6Gal-1 Sialyltransferase in Inflammation
ST6Gal-1 唾液酸转移酶在炎症中的作用
  • 批准号:
    10159705
  • 财政年份:
    2020
  • 资助金额:
    $ 60.99万
  • 项目类别:
ST6Gal-1 Sialyltransferase in Inflammation
ST6Gal-1 唾液酸转移酶在炎症中的作用
  • 批准号:
    10230376
  • 财政年份:
    2020
  • 资助金额:
    $ 60.99万
  • 项目类别:
ST6Gal-1 Sialyltransferase in Inflammation
ST6Gal-1 唾液酸转移酶在炎症中的作用
  • 批准号:
    9770765
  • 财政年份:
    2018
  • 资助金额:
    $ 60.99万
  • 项目类别:
ST6Gal I sialyltransferase in hematopoiesis
ST6Gal I 唾液酸转移酶在造血中的作用
  • 批准号:
    8452723
  • 财政年份:
    2011
  • 资助金额:
    $ 60.99万
  • 项目类别:
ST6Gal I sialyltransferase in hematopoiesis
ST6Gal I 唾液酸转移酶在造血中的作用
  • 批准号:
    8827236
  • 财政年份:
    2011
  • 资助金额:
    $ 60.99万
  • 项目类别:
ST6Gal I sialyltransferase in hematopoiesis
ST6Gal I 唾液酸转移酶在造血中的作用
  • 批准号:
    8645582
  • 财政年份:
    2011
  • 资助金额:
    $ 60.99万
  • 项目类别:
ST6Gal I sialyltransferase in hematopoiesis
ST6Gal I 唾液酸转移酶在造血中的作用
  • 批准号:
    8185890
  • 财政年份:
    2011
  • 资助金额:
    $ 60.99万
  • 项目类别:

相似海外基金

A platform for rapidly generating live attenuated enterovirus vaccines
快速生成减毒肠道病毒活疫苗的平台
  • 批准号:
    24K02286
  • 财政年份:
    2024
  • 资助金额:
    $ 60.99万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
I-Corps: Translation potential of an efficient method to generate live-attenuated and replication-defective DNA viruses for vaccine development
I-Corps:一种有效方法的转化潜力,可生成用于疫苗开发的减毒活病毒和复制缺陷型 DNA 病毒
  • 批准号:
    2420924
  • 财政年份:
    2024
  • 资助金额:
    $ 60.99万
  • 项目类别:
    Standard Grant
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
  • 批准号:
    10596047
  • 财政年份:
    2023
  • 资助金额:
    $ 60.99万
  • 项目类别:
Live attenuated non-transmissible (LANT) Klebsiella pneumoniae vaccines
肺炎克雷伯氏菌减毒非传染性 (LANT) 活疫苗
  • 批准号:
    10742028
  • 财政年份:
    2023
  • 资助金额:
    $ 60.99万
  • 项目类别:
Protecting Pigs From Enzootic Pneumonia: Rational Design Of Safe Attenuated Vaccines.
保护猪免受地方性肺炎:安全减毒疫苗的合理设计。
  • 批准号:
    BB/X017540/1
  • 财政年份:
    2023
  • 资助金额:
    $ 60.99万
  • 项目类别:
    Research Grant
A “Goldilocks” live attenuated poultry vaccine for Infectious Coryza
用于传染性鼻炎的“Goldilocks”家禽减毒活疫苗
  • 批准号:
    LP210301365
  • 财政年份:
    2023
  • 资助金额:
    $ 60.99万
  • 项目类别:
    Linkage Projects
A novel live-attenuated Zika vaccine with a modified 5'UTR
一种带有改良 5UTR 的新型寨卡减毒活疫苗
  • 批准号:
    10730832
  • 财政年份:
    2023
  • 资助金额:
    $ 60.99万
  • 项目类别:
Combating melanoma with an attenuated bacterial therapeutic
用减毒细菌疗法对抗黑色素瘤
  • 批准号:
    10659841
  • 财政年份:
    2023
  • 资助金额:
    $ 60.99万
  • 项目类别:
Investigating Host and Viral Factors for Improved Design of Future Live Attenuated Vaccines for IBV
研究宿主和病毒因素以改进未来 IBV 减毒活疫苗的设计
  • 批准号:
    BB/V016067/1
  • 财政年份:
    2022
  • 资助金额:
    $ 60.99万
  • 项目类别:
    Research Grant
L2M NSERC-Bioengineering attenuated Sclerotinia sclerotiorum strains as bioherbicide for cereal production and lawn management
L2M NSERC-生物工程减毒核盘菌菌株作为谷物生产和草坪管理的生物除草剂
  • 批准号:
    576545-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 60.99万
  • 项目类别:
    Idea to Innovation
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了